AI in Medicine - curated summaries making complex issues easy to understand podcast

Company Spotlight: iSchemaview Rapid MLS - Automating Brain Midline Shift on CT

0:00
14:12
Manda indietro di 15 secondi
Manda avanti di 15 secondi

We review the FDA 510(k) summary for iSchemaview's Rapid MLS, an AI software designed to measure brain midline shift from non-contrast CT scans. The episode unpacks the algorithm's performance against human experts, its clinical indications for intracranial hemorrhage and TBI, and the regulatory strategy of claiming substantial equivalence to a heart measurement tool.

Key points

  • Rapid MLS uses AI/ML to measure brain midline shift on non-contrast CTs, providing a color overlay and quantitative JSON output.
  • The software was cleared via the 510(k) pathway by claiming substantial equivalence to a predicate device that measures heart ventricles from CT pulmonary angiography (Rapid RV/LV).
  • In final performance validation on 153 cases, Rapid MLS achieved a mean absolute error of 0.7 mm, compared to the 3 experts' average pairwise error of 1.0 mm.
  • Validation data included a demographic split of 44% male and 56% female, spanning ages 26-93 years, sourced from 13 independent sites.
  • The device is not intended for stand-alone clinical decision-making and remains restricted to sale by or on the order of a physician.

Source: FDA 510(k) summary K243378: Rapid MLS (iSchemaview) - U.S. Food and Drug Administration, 2025

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: iSchemaview (ischemaview.com) · Product: Rapid MLS · FDA 510(k) K243378

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-ischemaview-rapid-mls-automating-brain-midline-shift-a59fcb

Altri episodi di "AI in Medicine - curated summaries making complex issues easy to understand"